The Development of New Spirooxindoles Targeting the p53–MDM2 Protein-Protein Interactions for Cancer Therapy

2018 ◽  
pp. 213-237 ◽  
Author(s):  
Bin Yu ◽  
Hong-Min Liu
Keyword(s):  
Cancer Therapy ◽  
Protein Interactions ◽  
Protein Protein Interactions ◽  
Mdm2 Protein

scholarly journals Exploring Protein-Protein Interactions as Drug Targets for Anti-cancer Therapy with In Silico Workflows

2017 ◽  
pp. 221-236 ◽  
Author(s):  
Alexander Goncearenco ◽  
Minghui Li ◽  
Franco L. Simonetti ◽  
Benjamin A. Shoemaker ◽  
Anna R. Panchenko
Keyword(s):  
Cancer Therapy ◽  
Protein Interactions ◽  
In Silico ◽  
Drug Targets ◽  
Protein Protein Interactions ◽  
Anti Cancer

Targeting protein–protein interactions for cancer therapy

2005 ◽  
Vol 83 (12) ◽  
pp. 955-963 ◽  
Author(s):  
David C. Fry ◽  
Lyubomir T. Vassilev
Keyword(s):  
Cancer Therapy ◽  
Protein Interactions ◽  
Protein Protein Interactions

scholarly journals Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy

2017 ◽  
Vol 26 (12) ◽  
pp. 2334-2341 ◽  
Author(s):  
Meng Gao ◽  
Jingjing Zhou ◽  
Zhengding Su ◽  
Yongqi Huang
Keyword(s):  
Cancer Therapy ◽  
Protein Interactions ◽  
Cellular Signaling ◽  
Signaling Networks ◽  
Protein Protein Interactions

Small-molecule modulation of p53 protein-protein interactions

2020 ◽  
Vol 401 (8) ◽  
pp. 921-931 ◽  
Author(s):  
Ave Kuusk ◽  
Helen Boyd ◽  
Hongming Chen ◽  
Christian Ottmann
Keyword(s):  
Tumor Suppressor ◽  
Small Molecules ◽  
Small Molecule ◽  
Protein Interactions ◽  
P53 Protein ◽  
Tumor Suppressor Protein ◽  
Protein Protein Interactions ◽  
Mdm2 Protein ◽  
Protein Protein Interaction ◽  
Altered Proteins

AbstractSmall-molecule modulation of protein-protein interactions (PPIs) is a very promising but also challenging area in drug discovery. The tumor suppressor protein p53 is one of the most frequently altered proteins in human cancers, making it an attractive target in oncology. 14-3-3 proteins have been shown to bind to and positively regulate p53 activity by protecting it from MDM2-dependent degradation or activating its DNA binding affinity. PPIs can be modulated by inhibiting or stabilizing specific interactions by small molecules. Whereas inhibition has been widely explored by the pharmaceutical industry and academia, the opposite strategy of stabilizing PPIs still remains relatively underexploited. This is rather interesting considering the number of natural compounds like rapamycin, forskolin and fusicoccin that exert their activity by stabilizing specific PPIs. In this review, we give an overview of 14-3-3 interactions with p53, explain isoform specific stabilization of the tumor suppressor protein, explore the approach of stabilizing the 14-3-3σ-p53 complex and summarize some promising small molecules inhibiting the p53-MDM2 protein-protein interaction.

scholarly journals Interfering with protein-protein interactions: Potential for cancer therapy

Cell Cycle ◽  
2008 ◽  
Vol 7 (11) ◽  
pp. 1569-1574 ◽  
Author(s):  
Tomoyuki Tanaka ◽  
Terence H. Rabbitts
Keyword(s):  
Cancer Therapy ◽  
Protein Interactions ◽  
Protein Protein Interactions

Modulating Protein–Protein Interactions In Vivo via Peptide-Lanthanide-Derived Nanoparticles for Hazard-Free Cancer Therapy

2019 ◽  
Vol 15 (9) ◽  
pp. 1937-1947 ◽  
Author(s):  
Guang Yang ◽  
Jun Zhang ◽  
Jin Yan ◽  
Weiming You ◽  
Peng Hou ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Protein Interactions ◽  
Protein Protein Interactions
Sign in / Sign up

Export Citation Format

Share Document